[Interaction of the complex copper compound Cu-2 with liver monooxygenases].
It has been shown that the antitumour drug Cu-2 (copper complex compound) inhibited the activity of liver monooxygenases in male CBA mice. The in vivo experiments have revealed a considerably increased duration of sleep in mice treated with hexenal after the administration of different Cu-2 doses. In vitro, after the incubation of intact mouse liver microsomal fractions with different concentrations of Cu-2 the level of cytochrome Y-450 was decreased and a non-active form of hemoprotein--cytochrome P-420--appeared. At the same time, after the incubation of Cu-2 with liver microsomal fractions stabilized by 20% glycerol type I spectral changes (Ks 330 microM) were registered. This shows the possible metabolism of Cu-2 by cytochrome P-450. The role of the revealed interaction of Cu-2 with liver microsomes is being discussed for the chemotherapy of cancer.
Bogush
T A
TA
Donenko
F V
FV
Sitdikova
S M
SM
Andronova
N V
NV
D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D003300:Copper / Q000493:pharmacokinetics* / Q000494:pharmacology; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006591:Hexobarbital / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology*; D010105:Oxygenases / Q000378:metabolism*; D012890:Sleep / Q000187:drug effects; D013997:Time Factors
D000970:Antineoplastic Agents; D003300:Copper; D003577:Cytochrome P-450 Enzyme System; D006591:Hexobarbital; D010105:Oxygenases
Vzaimodeĭstvie kompleksnogo soedineniia medi Cu-2 s monooksigenazami pecheni.